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Human O
6-alkylguanine-DNA alkyltransferase (hAGT) is a DNA repair protein that reverses the eﬀects of alkylating agents by
removing DNA adducts from the O
6 position of guanine. Here, we developed a real-time ﬂuorescence hAGT activity assay that
is based on the detection of conformational changes of the thrombin-binding aptamer (TBA). The quadruplex structure of TBA
is disrupted when a central guanine is replaced by an O
6-methyl-guanine. The sequence also contains a ﬂuorophore (ﬂuorescein)
and a quencher (dabsyl) attached to the opposite ends. In the unfolded structure, the ﬂuorophore and the quencher are separated.
When hAGT removes the methyl group from the central guanine of TBA, it folds back immediately into its quadruplex structure.
Consequently, the ﬂuorophore and the quencher come into close proximity, thereby resulting in decreased ﬂuorescence intensity.
Here, we developed a new method to quantify the hAGT without using radioactivity. This new ﬂuorescence resonance energy
transfer assay has been designed to detect the conformational change of TBA that is induced by the removal of the O
6-methyl
group.
1.Introduction
Alkylating agents are chemotherapeutic anticancer drugs
that produce their cytotoxic eﬀect by generating adducts at
multiple sites in DNA [1]. A subset of alkylating agents,
which includes nitrosoureas and temozolamide, have a
preference for alkylating guanine at the O6 position, which is
themostrelevantintermsofmutagenesisandcarcinogenesis
[2–9]. In particular, 1,3-bis-(2-chloroethyl)-1-nitrosourea
(BCNU) attacks initially at the O6 guanine position, causing
its rearrangement in a cyclic intermediate thus giving rise
to N1,O6-ethanoguanine [10]. Finally, a cross-link with
the opposite cytosine is formed, and, as a consequence,
DNA replication is blocked, producing G2/M arrest [11].
In addition to the well-known side eﬀects and limitations
of chemotherapeutic agents, these substances also present
problems of acquired tumor resistance. In particular, the
DNA-repair human O6-alkylguanine DNA alkyltransferase
(hAGT or MGMT) is responsible for removing alkyl adducts
from the O6 position of guanines, thereby blocking the
cytotoxic eﬀects of the alkylating agents and making a crucial
contribution to the resistance mechanism [12–14]. It is well
established that tumor cells show greater expression of this
protein than healthy cells. Thus, this increased expression
appears to be predictive of a poor response to chemother-
apeutic drugs. This eﬀect has been observed in a large
number of cancers, ranging from colon cancer, lung tumors,
breast cancer, pancreatic tumors, non-Hodgkin’s lymphoma,
myeloma, and glioblastoma multiforme, among others [15–
17]. In addition methylation of the hAGT promoter and
consequently the complete depletion of hAGT, it has been
associated with longer survival in patients with gliomas
undergoing combined radiation-chemotherapy treatment
[18, 19]. Therefore, pharmacological inhibition of hAGT has
the potential to enhance the cytotoxicity of a diverse range of
anticancer agents [20].2 Journal of Nucleic Acids
hAGT is a 22-kDa (207 AA) DNA-binding protein that
contains a highly conserved internal cysteine, which acts as
the acceptor site for alkyl groups. The S-alkyl-Cys formed
is not regenerated and the protein, which behaves as a
suicidal enzyme, inactivates itself in the dealkylation process
[21, 22]. This single turnover of hAGT renders it vulnerable
to inactivation. On the basis of this observation, intense
research eﬀort has been devoted to the identiﬁcation of
small molecules capable of inhibiting hAGT activity and
signiﬁcantly enhancing the cytotoxic eﬀect of BCNU in
prostate, breast, colon, and lung tumor cells [20].
Several methods are available to characterize the mech-
anism of action of hAGT and its activity. Moreover, they
also have the capacity to evaluate the capacity of small
molecules to inhibit hAGT. Most of these methods are based
on radioactivity assays while others are based on multiple-
step enzymatic reactions [23–26].
G-quadruplexes are a family of four-stranded DNA
structures stabilized by the stacking of guanine tetrads, in
which four planar guanines form a cyclic array of hydrogen
bonds [27]. These G-rich regions are connected by lateral,
central, or diagonal loops of diverse sizes and composition
that form base-pairing alignments, which in turn stack
with the terminal G-tetrads, thus further stabilizing G-
quadruplex structures [28]. Another key element in G-
quadruplex formation is the presence of monovalent cations,
which stabilize the negative electrostatic potential created by
the guanine O6 oxygen atoms within the quadruplex core
[29, 30]. However, most divalent cations have the capacity
to induce the dissociation of G-quadruplex structures [31].
Finally, modiﬁcations in the base composition of the tetrads
are poorly tolerated by these structures. As an example,
inosine [32]a n dO 6-methylguanine [33], both nonnatural
basescanformasmallernumberofhydrogenbondsandthus
destabilize the G-quadruplex.
Given the potential relevance of hAGT as a prognostic
marker of cancer and as a therapeutic target, and that
its substrate O6-methylguanine disrupts the formation of
G-quadruplex structures [33], here, we developed a new
ﬂuorescence activity assay for hAGT. For this purpose, we
selected the thrombin-binding aptamer (TBA) as our G-
quadruplex model. TBA is a well-known 15 mer that adopts
a chair-like structure consisting of two G-tetrads connected
by two lateral TT loops and a central TGT loop [34]. The
modiﬁcation of its sequence in positions 5 or 6 by replacing
a guanine of the tetrad for an O6-methylguanine disrupts
folding, leaving it in an extended conformation. Giving that
the two conformations bring the two ends of TBA together
take them further apart, our working hypothesis was that the
incorporation of ﬂuorescence probes results in a measurable
change in intensity. The ﬁnal aim of this ﬂuorescence assay
was to measure the DNA repair activity of hAGT and thus
facilitate the search for new and more potent inhibitors
which enhance chemotherapeutic drugs. Although several
methods have been described to quantify hAGT activity [23–
26], none of them use the conformational change of G-
quadruplex for this purpose. Here, we describe the devel-
opment of a straightforward, rapid, one-step ﬂuorescence
resonance energy transfer (FRET) assay.
2.MaterialsandMethods
2.1. Chemicals. 5 -Fluorescein CE phosphoramidite (6-
FAM), 3 -Dabsyl CPG, O6-methylguanine (O6-MeG) and
Gdmf phosphoramidites were purchased from Link tech-
nologies (UK) and Glen Research (USA). O6-methylguanine
was protected with the isobutyryl group [35]. Standard
phosphoramidites and ancillary reagents were purchased
from Applied Biosystems (Europe).
ThematricesforMALDI-TOFexperimentswere2 ,4 ,6 -
trihydroxiacetophenone monohydrate (THAP) and ammo-
nium citrate dibasic.
Solvents for chromatographic analysis were prepared
using triethylamine, acetic acid, and acetonitrile as mobile
phase. All other chemicals were of analytical reagent grade
and were used as supplied. Ultrapure water (Millipore, USA)
was used in all experiments.
2.2. Instrumentation. Semipreparative reverse phase (RP)
HPLC was performed on a Waters chromatography system
using Nucleosil semipreparative 120 C18 (250 × 8mm)
columns. Analytical RP-HPLC was performed using an
XBridge OST C18 2.5μm column and a Nucleosil Analytical
column 120 C18 (250 × 4mm). Oligonucleotides were
detected by UV absorption at 260nm. Mass spectra were
recorded on a MALDI Voyager DETM RP time-of-ﬂight
(TOF) spectrometer (Applied Biosystems, USA) with a
nitrogen laser at 337nm using a 3-ns pulse. Fluorometric
measurements were performed on a spectroﬂuorometer
multidetection microplate reader Biotek FL × 800 and a
JascoFP6200.Molecularabsorptionspectrabetween220and
550nm were recorded with a Jasco V650 spectrophotometer.
The temperature was controlled with a Jasco ETC 272T
Peltier device. Hellma quartz cuvettes (0.5 and 1.0cm path
length, 500 or 1000μL volume) were used.
2.3. Oligonucleotide Synthesis. Oligonucleotide sequences
(shown in Table 1) were synthesized on an ABI 3400
DNA Synthesizer (Applied Biosystems, USA) using a 200-
nmol scale synthesis and following the standard proto-
cols. We used dimethylformamidino-protected guanine Gdmf
phosphoramidite for all the syntheses. 5 -Fluorescein CE
phosphoramidite (6-FAM), O6-methylguanine (O6-MeG)
and Gdmf phosphoramidites were from commercial sources.
The isobutyryl group was used to protect the amino group
of O6-MeG [35]. The quencher group was introduced at
the 3  end using the controlled pore glass functional-
ized with a 3 -Dabsyl derivative CPG. O6-MeG-containing
oligonucleotidesweredeblockedusingconcentratedaqueous
ammoniaovernightatroomtemperaturefollowingtheman-
ufacturer’sinstructions.Theresultingproductsweredesalted
by Sephadex G-25 (NAP-10, GE Healtcare, USA) and puri-
ﬁed by reversed-phase HPLC using Nucleosil columns. The
yields and purities obtained for the products were around
85% for 5-O6-MeG-TBA and 6-O6-MeG-TBA, and >98%
for the rest of the sequences. The length and homogene-
ity of the oligonucleotides were checked by MALDI-TOF.Journal of Nucleic Acids 3
Table 1: Sequences of TBA oligonucleotide derivatives used in the development of the hAGT ﬂuorescence assay. MeG represents O6-
methylguanine. MB represents the ﬂuorophore group (FAM), labelled in the 5  end, and the quencher group (Dabsyl), labelled in the 3 
end of the sequence.
Abbreviation Sequence
TBA 5 -GGT TGG TGT GGT TGG-3 
5-O6-MeG-TBA 5 -GGT T MeGG TGT GGT TGG-3 
6-O6-MeG-TBA 5 -GGT TG MeGTGT GGT TGG-3 
C-TBA 5 -CCA ACC ACA CCA ACC-3 
MB-TBA 5 -FAM-GGT TGG TGT GGT TGG-Dabsyl-3 
MB-5-O6-MeG-TBA 5 -FAM-GGT T MeGG TGT GGT TGG- Dabsyl-3 
MB-6-O6-MeG-TBA 5 -FAM-GGT TG MeG TGT GGT TGG- Dabsyl-3 
3-HP-TBA 5 -A CCT TTT GGT TGG TGT GGT TGG-3 
6-HP-TBA 5 -C CAA CCT TTT GGT TGG TGT GGT TGG-3 
9-HP-TBA 5 -A CAC CAA CCT TTT GGT TGG TGT GGT TGG-3 
5-O6-MeG-TBA [M] = 4731.7 (expected 4737.8), 6-O6-
MeG-TBA [M] = 4729.9 (expected 4737.8), MB-5-O6-MeG-
TBA [M] = 5828.49 (expected 5826.0), MB-6-O6-MeG-TBA
[M] = 5826.80 (expected 5826.0).
The DNA-strand concentration was determined by
absorbance measurements (260nm) by calculating extinc-
tion coeﬃcients. Oligonucleotide samples were kept at
4◦C until further use. Double-stranded O6-MeG-TBA was
formed by annealing equimolar concentrations of comple-
mentary oligonucleotide strands at 72
◦C for 5 min and then
allowed to slowly cool to room temperature.
2.4. Melting Temperature Studies. Melting curves were mea-
sured by monitoring the absorbance hyperchromicity at 295
and 495nm in a JASCO V650 spectrophotometer equipped
with a Peltier temperature-controlling unit. UV/Vis absorp-
tion spectra were recorded at 1◦C/min intervals, with a 1-
min equilibration time at each temperature; the sample was
heated over the range 20–80
◦C. The buﬀer solutions used
were 10mM sodium cacodylate pH 7.0 and 100mM KCl.
Sample concentration was around 4μM. Each sample was
allowed to equilibrate at the initial temperature without any
external control of temperature for 5 min before the melting
experiment began. The melting temperatures (Tm) are the
average value of at least one pair of Tm experiments.
2.5. CD Spectra. Samples were prepared as described for
the melting experiments by UV spectroscopy. Measurements
were conducted in 10mM sodium cacodylate pH 7.0 and
100mM KCl. Sample concentration was between 1–4μM.
The CD spectra were recorded on a Jasco J-810 spectropo-
larimeter attached to a Julabo F/25HD circulating water bath
in 1cm path-length quartz cylindrical cells. Spectra were
recorded at room temperature using a 100nm/min scan rate,
a spectral band width of 1nm and a time constant of 4s. All
the spectra were corrected with the buﬀer blank and plotted
using Origin software.
2.6. Human Recombinant hAGT Protein. Full-length hAGT
was overexpressed and puriﬁed as previously described [36].
Brieﬂy, hAGT protein cloned in the pet-21a (+) (Novagen)
vector was expressed in the E. coli strain Rosetta. Once the
culture reached an OD600 value of 0.98, hAGT was induced
by adding 1mM IPTG (Sigma) and left for 4h at 30
◦C.
The pellet from a 1-L culture was disrupted by sonication
and centrifuged. The supernatant was ﬁltered, loaded into
a HiTrap FF column (GE Healthcare) with buﬀer 350mM
N aCl,20mMT rispH8,20mMimidazole,and1mMBME,
and then eluted with an imidazole (Fluka) gradient up to
500mM in the same buﬀer. Finally, the protein was loaded
into a Superdex 75 16/60 column (GE Healthcare) with the
following buﬀer: 200mM NaCl (Merck), 20mM Tris pH 8.0
(Merck), 10mM DTT (Sigma) and 0.1mM EDTA (Sigma).
The protein was concentrated to 2mg/mL in this buﬀer and
kept at −20
◦C in the presence of 40 % glycerol. The same
protocol was used for the puriﬁcation of the inactive mutant
hAGT-C145S, cloned in the pet-28a (+) vector (Novagen),
and expressed in the E. coli strain BL21.
2.7. HPLC hAGT Assay. Assays were conducted using
double-stranded5-O6-MeGand6-O6-MeGTBApairedwith
TBA complementary sequence or using single-stranded 5-
O6-MeG and 6-O6-MeG TBA.
InordertomeasurethedealkylationofO6-MeG,50pmol
of the O6-MeG-TBA substrates were incubated with a range
of concentration of hAGT (16nM to 1.6μM) to a ﬁnal
volume of 120μLi nar e a c t i o nb u ﬀer (200mM NaCl,
50mM Tris pH 8.0, 1mM DTT, and 5mM EDTA). Several
incubation times were tested (30, 60, 90, 120, 360, and 1440
min) at 37
◦C and the reaction was stopped by heating the
samples at 72
◦C for 5 min. The reaction products were
analyzed by HPLC on a Nucleosil analytical column at 60
◦C
or room temperature, depending on the substrates used
in the experiment (double- or single-stranded TBA). The
HPLC ﬂow rate was 1mL/min, and a gradient of 10%–40%
acetonitrile for 20 min was used.
2.8. Fluorescence Assay for hAGT Activity. The ﬂuorescence
assay was performed in a multidetection microplate reader
biotek FLx800 in optical 96-well Optical btm reaction plates4 Journal of Nucleic Acids
Me
hAGT
Me-hAGT
5 -FAM 3 -DABSYL
5 -FAM
5 -FAM
3 -DABSYL
3 -DABSYL
Figure 1: Scheme of ﬂuorescence-based hAGT assay. The sub-
strate is the thrombin-binding aptamer modiﬁed by an O6-
methylguanine (Me) in extended conformation, with a ﬂuorophore
andquencherintheoppositeendsofthesequence.Therefoldofthe
G-quadruplex structure of TBA is dependent on the removal of the
methyl adduct by alkyl-guanine-DNA-O6-alkyltransferase (hAGT).
This repair moves the quencher and the ﬂuorophore molecules in
close proximity and blocks ﬂuorescence.
(Nunc, USA). Full-length hAGT recombinant protein (207
amino acids) was used for the assay and the hAGT-C145S
inactive mutant was used as a negative control. The reaction
was performed in a total volume of 50μLi ne a c hw e l l ,
incubating increasing concentrations of hAGT (5, 10, 20,
40, 60, and 80nM) enzyme in reaction buﬀer (200mM
NaCl, 50mM Tris pH 8.0, 1mM DTT, 5mM EDTA, and
20mM KCl). The assay of hAGT was then initiated by the
addition of 5μLo fd i ﬀerent concentrations (5, 10, 25, and
50nM) of ﬂuorescently labelled MB-O6-MeG-TBA substrate
and this solution was then placed in a microplate reader
system. Fluorescence was measured every minute for 20 min
or 40 min at excitation and emission wavelengths of 485 and
535nm, respectively. Averages over three readings were taken
for each condition tested. Each experiment was performed in
triplicate.
3. Results andDiscussion
The aim of this study was to develop a real-time hAGT
activity assay based on the detection of diﬀerences between
extended and folded conformations of TBA. Our working
hypothesis was that the quadruplex structure of TBA is
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Figure 2: CD spectra of MB-TBA and MB-5-O6-MeG-TBA at
25
◦C. Buﬀer conditions: 10mM sodium cacodylate pH 7.0 and
100mM KCl, sample concentration 1μM.
disrupted when a central guanine is replaced by an O6-
methylguanine. The TBA sequence also contains a ﬂuo-
rophore and a quencher group attached to 5  or 3  end,
respectively. In the presence of O6-methylguanine, methy-
lated TBA unfolds and the ﬂuorophore and the quencher
become physically separated beyond the F¨ orster distance.
When the repair protein hAGT is added to the methylated
aptamer, the enzyme removes the methyl group from the
mutated guanine, thus allowing TBA to fold back into its
chair-like conformation. As a result, the quencher comes
closer to the ﬂuorophore and blocks its ﬂuorescence, as
illustrated in Figure 1. This loss of ﬂuorescence is quantiﬁed
as a direct measurement of hAGT activity.
3.1. Synthesis of Modiﬁed G-Quadruplex Sequences. The G-
quadruplex sequences used in this study are shown in
Table 1. Oligonucleotide synthesis was performed by the
solid-phase 2 -cyanoethyl-phosphoramidite method [37].
Ammonia treatment was performed at room temperature
overnight to minimize decomposition of O6-methylguanine.
For the same reason, the dimethylformamidino group was
selected for the protection of 2 -deoxyguanosine [38]. The
sequences were characterized by HPLC and mass spectrom-
etry, which provided the expected molecular weights. The
yields of the isolated molecular beacon oligonucleotides after
HPLC puriﬁcation and desalting were in the range of those
obtained for unmodiﬁed oligonucleotides.
3.2. Thermal Stability of Methylguanine-Modiﬁed TBA. In
order to induce the unfolding of the quadruplex structure
of TBA, we introduced an O6-methyl-guanine at position
5 or 6 of TBA. Melting curves of the modiﬁed sequences
w e r ep e r f o r m e db yU Vs p e c t r o s c o p ya n dc o m p a r e dw i t h
the unmodiﬁed sequence. These experiments were carriedJournal of Nucleic Acids 5
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Figure 3: Schematic representation of the structure of several derivatives of thrombin-binding aptamers (TBAs) prepared in this study.
TBA sequence is shown in black, and T4 loop with diﬀerent sizes of the complementary sequences are shown in red. (a) Native TBA;
(b) TBA-hairpin containing three overhanging complementary nucleotides (3-HP-TBA); (c) TBA-hairpin containing six overhanging
complementary nucleotides (6-HP-TBA); (d) TBA-hairpin containing nine overhanging complementary nucleotides (9-HP-TBA). Between
3–6 complementary nucleotides are required to disrupt the intramolecular quadruplex to form an intramolecular duplex.
out at pH 7 in buﬀer containing 10mM sodium cacody-
late and 100mM KCl, which is predicted to stabilize G-
quadruplexes structures. We did not observe a melting
temperature at 295nm for 5-O6-MeG-TBA or 6-O6-MeG-
TBA and the corresponding molecular beacons (see Figures
S1–S4 in Supplementary Data Material available online at
doi: 10.4061/2010/632041). The absence of this transition is
consistent with the disruption of the quadruplex structure.
These results contrast with the melting temperature of native
TBA(Tm48
◦C)andMB-TBA(Tm46
◦C).Moreover,circular
dicroism of methylated-TBA derivatives did not show the
presence of the maximum at 295nm, which is characteristic
of the antiparallel quadruplex of TBA (Figure 2 and Figure
S5). These results conﬁrmed that methylation of guanine in
either of the two positions of the TBA sequence prevents the
formation of the chair structure. This observation conﬁrms
our working hypothesis.
Given that the DNA repair activity exerted by hAGT
is higher in double-stranded DNA than single-stranded
DNA [39], we studied the stability and the quadruplex
formation of elongated self-complementary TBA derivatives
(see Table 1). We designed several TBA oligonucleotides
elongatedintheir3  endwithasubsetofself-complementary
sequences of diverse sizes. The purpose of these elongations
was to check whether the extended sequences have the
capacity to form a double strand helix of diﬀerent lengths
and strengths with themselves without disrupting the chair-
like structure. For 6-HP-TBA and 9-HP-TBA, we found that
the corresponding Tm at 260nm were 63oCa n d7 1 .8
◦C,
respectively. This observation conﬁrms our hypothesis of
a double helix structure that increases in strength as the
sequence length increases. However, we did not detect a
melting temperature of these two sequences at 295nm.
The absence of a transition at 295nm is consistent with
the absence of an antiparallel quadruplex structure. In
contrast, 3-HP-TBA, corresponding to an overhang of only
3 nucleotides, gave a melting temperature of 46
◦C at 295nm,
whichisslightlybutsimilartothatobtainedfornaturalTBA.
This result indicates that 3-HP-TBA forms an antiparallel
quadruplex instead of a duplex because the overhang is too
short to break the chair-like structure. Circular dichroism
conﬁrms the quadruplex structure of 3-HP-TBA and the
absence of quadruplex structure in 6-HP-TBA and 9-HP-
TBA (Figure S6). Models of all these structures are shown
in Figure 3.
3.3. HPLC Analysis of DNA Repair Activity of hAGT. In order
to observe the eﬃciency of hAGT to remove alkyl groups
from single-stranded oligonucleotides, we performed several
assays to determine the optimal conditions of the reaction.
For this purpose, the full-length hAGT was ﬁrst over-
expressed and puriﬁed as described previously [36]. Increas-
ing concentrations of the protein were incubated with
double-stranded 5-O6-MeG and 6-O6-MeG TBA, annealed
with its complementary sequence. Figure 4(a) shows the
HPLC proﬁle of the ﬁnal product of the reaction with
double-stranded 5-O6-MeG-TBA. In order to separate the
two strands of the TBA substrate (Figure 4(a) top right
panel), HPLC analyses were done at 60
◦C. After incubation
with hAGT, we detected a peak with a shorter retention time,
which corresponds to the restored TBA sequence caused by6 Journal of Nucleic Acids
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Figure 4: HPLC analysis of hAGT activity over double- and single-stranded TBA before and after incubation with hAGT. (a) Repair of
double-stranded 5-O6-MeG-TBA by hAGT. The peak labelled as cTBA corresponds to the complementary sequence of 5-O6-MeG-TBA.
The top right panel shows HPLC chromatogram in absence of hAGT. The gradient was from 10%–40% acetonitrile for 20 min at 60
◦C. (b)
Repair of single- stranded5-O6-MeG-TBAby hAGT.Theinsertedpanel showsHPLC chromatogram inthe absence ofhAGT.Gradient used:
10%–40% acetonitrile, 20 min at room temperature.
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Figure 5: Fluorescence intensity of the real-time hAGT assay, measured at excitation and emission wavelengths of 485nm and 535,
respectively. (a) Illustration of the diﬀerent controls with 5nM MB-5-O6-MeG-TBA: (1) Positive control of MB-5-O6-MeG-TBA in the
absence of hAGT; (2) Intensity in presence of the inactive mutant hAGT-C145S; (3) Decrease in ﬂuorescence when adding 40nM active
hAGT; and (4) basal ﬂuorescence of 5nM of MB-TBA. (b) Decrease in intensity caused by the activity of hAGT at a range of concentrations
(0, 20, 40, and 60nM), in all of them the basal ﬂuorescence of MB-TBA was subtracted.
the removal of the methyl group. We obtained the same
results when we used double-stranded 6-O6-MeG-TBA as a
substrate (data not shown). As expected, hAGT activity was
not aﬀected by the position of the alkyl group within the
sequence. We then tested hAGT activity over single-stranded
methylated TBA in the previously optimized conditions
and obtained similar results to those shown in Figure 4(b).
The top right panel shows the HPLC chromatogram in the
absence of hAGT. In this case, the HPLC analyses were
performed at room temperature because the substrate was
single-stranded TBA. Our results conﬁrmed that hAGT has
thecapacitytoremovemethylgroupsfromsingle-ordouble-
stranded TBA with the same eﬃcacy. Therefore, we selected
single-stranded TBA as substrate for the development of our
ﬂuorescence assay.
3.4. Fluorescence hAGT Activity Assay. On the basis of the
results obtained in the melting temperature and the HPLC
experiments, we tested the eﬀectiveness of our proposed
model to the DNA repair activity of hAGT by means of
ﬂuorescence. First of all, we determined the minimum
amount of TBA required to achieve a detectable and reliableJournal of Nucleic Acids 7
diﬀerence in intensity compared to the background. As
expected, the negative control natural TBA quadruplex gave
low background ﬂuorescence, because of the proximity of
the ﬂuorophore and the quencher groups in the chair-like
structure (Figure 5(a)). Although the ﬂuorescence of MB-
TBA was low, this ﬂuorescence was subtracted from the
ﬂuorescence value in each experiment. The concentration
of 5nM of ﬂuorescently labelled MB-O6-MeG-TBA was
considered the optimal concentration as the ﬂuorescence
signal was intense and only a small amount of hAGT protein
was required to achieve a substantial decrease in ﬂuorescence
in 20–40 min. In the optimal conditions, the presence
of hAGT produced a remarkable decrease in ﬂuorescence
intensity, caused by the demethylation of the O6 position
of guanines, thereby allowing the TBA to form its typical
quadruplex structure, which brings together the ﬂuorophore
andthequenchergroups,asoccurredinthenegativecontrol.
T h er a t eo fd e c r e a s ei nﬂ u o r e s c e n c ei n t e n s i t yc o r r e l a t e d
directly with the amount of hAGT in the reaction mixture
(Figure 5(b)). Moreover, the inactive mutant hAGT-C145S
did not exhibit any decrease in ﬂuorescence (Figure 5(a)).
This result was expected because of the inability of this
mutated protein to repair the modiﬁed TBA. Figure 5(b)
shows the ﬂuorescence intensities for the real time hAGT
assay. All these observations are consistent with the hypothe-
sis and design of our FRET method.
4. Conclusion
Although radioactivity has been widely used in the search
of potential inhibitors of hAGT [23, 24], this technique
does not allow real-time data acquisition and, in addition,
requires radioactive materials. Here, we developed a sensitive
ﬂuorescence method that allows the quantiﬁcation of hAGT
activity in a single step and in a straightforward manner.
Although another ﬂuorescence method has already been
developed for this purpose [25], it requires the addition
of a restriction enzyme, followed by the addition of an
exonuclease after the hAGT activity reaction. Consequently,
although it is a real-time assay, a three-step reaction is
required before observing an increase in ﬂuorescence. In
contrast, in our assay, a change in ﬂuorescence is detected
in a single step (homogeneous), and this method does not
depend on the activity of two additional enzymes.
Our assay is based on the detection of conforma-
tional changes of TBA in the presence or absence of O6-
methylguanines in its structure. The quadruplex structure
of TBA is disrupted when a central guanine is replaced by
an O6-methylguanine. Fluorophore groups can be added to
the modiﬁed sequence in order to detect the conformational
changes by ﬂuorescence. The variation in ﬂuorescence can
be quantiﬁed as a direct measurement of hAGT activity. In
addition, this technique requires lower amounts of substrate
and does not call for the use of radioactive materials.
Furthermore, this method can be easily transferred to a high
throughputexperimentfortheevaluationofsmallmolecules
as potential hAGT inhibitors [36]. Research in this direction
is currently underway in the laboratory.
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